Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Free Cash Flow (2016 - 2025)

Vistagen Therapeutics' Free Cash Flow history spans 14 years, with the latest figure at -$17.8 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 71.23% year-over-year to -$17.8 million; the TTM value through Dec 2025 reached -$60.3 million, down 54.21%, while the annual FY2025 figure was -$42.1 million, 62.91% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$17.8 million at Vistagen Therapeutics, down from -$13.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.8 million in Q4 2023 and bottomed at -$18.8 million in Q2 2025.
  • The 4-year median for Free Cash Flow is -$10.4 million (2024), against an average of -$10.9 million.
  • The largest annual shift saw Free Cash Flow tumbled 837.16% in 2021 before it dropped 27.06% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$17.8 million in 2021, then skyrocketed by 73.26% to -$4.8 million in 2023, then plummeted by 117.9% to -$10.4 million in 2024, then tumbled by 71.23% to -$17.8 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Free Cash Flow are -$17.8 million (Q4 2025), -$13.8 million (Q3 2025), and -$18.8 million (Q2 2025).